Key Takeaways:
Medical professionals are issuing new warnings over a significant side effect of popular GLP-1 drugs, highlighting that the rapid weight loss they induce can include up to 25% of a person's lean body mass and muscle.
"It’s common to lose upwards of 20 to 25% lean body mass, which includes muscle," Dr. Richele Corrado, a spokesperson for The Obesity Society, said. "Rapid weight loss — which can happen on GLP-1 drugs — may increase that risk even further."
The side effects are widespread, with a 2022 clinical trial finding that approximately 80% of people taking tirzepatide (Zepbound) experienced at least one. While most common effects are gastrointestinal, the muscle loss component is gaining scrutiny as millions use the drugs. Inconsistent use may also backfire; a University of Pennsylvania study found mice that cycled off and on semaglutide regained weight, primarily as fat.
The growing concerns over muscle wasting and potential frailty introduce a significant headwind for the multi-billion dollar market dominated by Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Zepbound, potentially impacting future prescription growth and investor confidence.
The primary mechanism of GLP-1 drugs involves mimicking a hormone that slows digestion and signals fullness to the brain. This caloric deficit, while effective for weight loss, can also lead the body to break down muscle tissue for energy if not managed correctly.
Obesity medicine specialists recommend a two-pronged strategy to counteract this effect. The first is prioritizing protein intake, with experts suggesting 1.2 to 1.6 grams of protein per kilogram of body weight daily. For a 200-pound person, this translates to about 108 to 144 grams of protein per day.
The second critical component is resistance training. The U.S. Food and Drug Administration approves these medications for use alongside diet and exercise. Experts recommend at least two strength-training sessions per week to preserve muscle mass and overall strength.
Compounding the concerns is new research on inconsistent adherence. A study from the University of Pennsylvania's Leung Lab found that cycling mice on and off semaglutide, the active ingredient in Ozempic, caused them to regain weight as fat and made the drug less effective on subsequent cycles. With reports that more than half of human users stop taking the medication within two years, the findings raise questions about long-term outcomes for a large portion of patients.
The warnings about muscle loss represent a new challenge for a drug class that has seen explosive growth. For investors, the key question is whether these side effects will be perceived as a manageable part of treatment or a serious deterrent. The next earnings calls for Eli Lilly and Novo Nordisk will be closely watched for any commentary on prescription trends and patient retention.
This article is for informational purposes only and does not constitute investment advice.
